1-4 of 4
Manfred Fliegauf, PhD
Close
Sort by
Journal Articles

AML1/ETO-Mediated Lysozyme Repression Is Independently Relieved by Inhibitors of DNA Methylation and Histone Deacetylation.

Rainer Claus, MD, Manfred Fliegauf, PhD, Michael Stock, PhD, Jesus Duque, Mateusz Kolanczyk, PhD, Michael Lübbert, MD PhD
Journal: Blood
Blood (2006) 108 (11): 4310.
https://doi.org/10.1182/blood.V108.11.4310.4310
Published: 2006
Journal Articles

Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: P53-Independent Upregulation of P21/WAF/CIP1.

Tobias Berg, Manfred Fliegauf, PhD, Jurij Pitako, MD, Jan Burger, MD, Mahmoud Abdelkarim, Yalin Guo, MD, Martin S. Staege, PhD, Stefan Burdach, MD PhD, Michael Lübbert, MD PhD
Journal: Blood
Blood (2004) 104 (11): 2576.
https://doi.org/10.1182/blood.V104.11.2576.2576
Published: 2004
Journal Articles

Williams-Beuren Syndrome Critical Region-5/Non-T Cell Activation Linker: A Novel Target Gene of AML1/ETO.

Michael Lübbert, MD PhD, Michael Stock, PhD, Tobias Berg, Manfred Fliegauf, PhD
Journal: Blood
Blood (2004) 104 (11): 2898.
https://doi.org/10.1182/blood.V104.11.2898.2898
Published: 2004
Journal Articles

AML1/ETO Expresssion in Myeloid Leukemia Cells Is Associated with Enhanced Growth-Inhibitory and P15/INK4b Demethylating Effects of 5-AZA-2′-Deoxycytidine.

Tobias Berg, Mahmoud Abdelkarim, Yalin Guo, MD, Manfred Fliegauf, PhD, Michael Lübbert, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 1165.
https://doi.org/10.1182/blood.V104.11.1165.1165
Published: 2004